Renal Transplantasyon Sonrası Gelişen Solid Organ Kanserlerinin Kötü Sonlanımları: Tek Merkez Deneyimi

Öz

Amaç: Bu çalışmada, böbrek nakil sonrası solid organ kanseri gelişen hastalarda sağ kalımı etkileyen faktörlerin tanımlanması amaçlandı.Gereç ve Yöntemler: Bu retrospektif gözlemsel çalışmada birincil sonlanım noktası genel sağ kalım idi. Bulgular: Toplamada 39 hasta çalışmaya dahil edildi. Ortanca maligniteye kadar geçen süre 49 ay idi. Ortanca genel sağ kalım 24 aydı ve ortanca progresyonsuz sağ kalım 16 aydı. Primer tümör rezeksiyonu daha iyi OS p

Anahtar Kelimeler

• Solid kanserler, Böbrek nakli alıcısı, Sağ kalım

Poor Outcomes of Solid Organ Cancers After Renal Transplantation: A Single-Center Experience

Öz

Objective: This study aimed to describe survival and its influencing factors in post-renal transplant patients with solid organ cancers.Material and Methods: In this retrospective, observational study overall survival was the primary endpoint. Results: In total, 39 patients were included. The median malignancy development time after transplantation was 49 months. The median overall survival was 24 months and the median progression-free survival was 16 months. Primary tumor resection predicted better OS p

Anahtar Kelimeler

• Solid cancers, Renal transplant recipient, Survival

Kaynakça

1. Garcia GG, Harden P, Chapman J. The global role of kidney transplantation. Curr Opin Nephrol Hypertens 2012; 21:229-34.
2. Torbenson MS, Wang J, Nichols L, Jain AB, Fung JJ, Nalesnik MA. Occult nonhematopoietic malignancies present at autopsy in solid organ transplant patients who died within 100 days. Transplantation 2001; 71:64.
3. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346(8972):403-6.
4. Pecqueuxa JC, Schwarzb A, Dieckmanna KP, Offermannb G. Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int 1990; 45:290-2.
5. Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J 2015; 8:637-44.
6. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905-13.
7. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16:1545-9.
8. Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70:1335-42.

9. Gallo P, Agozzino L, Angelini A, Arbustini E, Bartoloni G, Bernucci P, Bonacina E, Bosman C, Catani G, di Gioia C, Giordana C, Leone O, Motta T, Pucci A, Rocco M. Causes of late failure after heart transplantation: A ten-year survey. J Heart Lung Transplant 1997; 16:1113- 21.
10. Sheil AGR, Disney APS, Mathew TH, Amiss, N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25:1383-4
11. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994; 99-109.
12. Dantal J, Pohanka E. Malignancies in renal transplantation:an unmet medical need. Nephrol Dial Transplant 2007; (Suppl 1):4-10.
13. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 354:93-9.
14. Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM. Immunosuppressive medications and squamous cell skin carcinoma: Nested case-control study within the Skin Cancer after Organ Transplant (SCOT) Cohort. Am J Transplant 2016; 16:565-73.
15. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5:2954-60.
16. Pascual J. The use of everolimus in renal-transplant patients. Int J Nephrol Renovasc Dis 2009; 2:9-21.
17. Gutiérrez-Dalmau A, Campistol JM. The role of prolif- eration signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007; (Suppl 1):11-6.
18. ANZDATA Registry Working Group. Chapter 10: Cancer Report. In ANZDATA Registry 31st Annual Report (ed). McDonald S, Excell L, Livingston B. Adelaide, Australia, 2008.
19. Lim WH, Badve SV, Wong G. Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study. Oncotarget 2017; 8:77771-82.
20. van de Wetering J, Roodnat JI, Hemke AC, Hoitsma AJ, Weimar W. Patient survival after the diagnosis of cancer in renal transplant recipients: A nested case-control study. Transplantation 2010; 90:1542-6.
21. Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A. Malignancy-related mortality following kidney transplantation is common. Kidney Int 2014; 85:1395-403.
22. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27:409- 13.
23. Apel H, Walschburger-Zorn K, Häberle L, Wach S, Engehausen DG, Wullich B. De novo malignancies in renal transplant recipients: Experience at a single center with 1882 transplant patients over 39 yr. Clin Transplant 2013; 27:30-6.
24. Lizakowski S, Kolonko A, Imko-Walczuk B, Komorowska- Jagielska K, Rutkowski B, Więcek A, Dębska-Ślizień A. Solid organ cancer and melanoma in kidney transplant recipients: TumorTx base preliminary results. Transplant Proc 2018; 50:1881-8.
25. Chapman JR, Webster AC. Cancer after renal transplantation: The next challenge. Am J Transplant 2004; 4:841-2.
26. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-9.
27. Rousseau-Gazaniol C, Fraboulet S, Couderc LJ, Kreis H, Borie R, Tricot L, Anglicheau D, Martinez F, Doubre H, Bonnette P, Mellot F, Massiani MA, Pelle G, Sage E, Moisson P, Delahousse M, Zemoura L, Chapelier A, Hamid AM, Puyo P, Longchampt E, Legendre C, Friard S, Catherinot E. Lung cancer in renal transplant recipients: A case-control study. Lung Cancer 2017; 111: 96-100.
28. Park JM, Choi MG, Yang CW, Jung CK, Lee SK, Yoon AR, Kim YS, Chung IS. Increased incidence of gastric cancer in renal transplant recipients. J Clin Gastroenterol 2012; 46:87-91.
29. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: Do patients and their oncologists agree? Br J Cancer 2003; 89:1022-7.
30. Caires-Lima R, Cayres K, Protásio B, Caires I, Andrade J, Rocha L, Takahashi TK, Hoff PM, de Castro G Jr, Mak MP. Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. Ecancermedicalscience 2018; 12:831.